Tyrosine Kinase Inhibitors Market

Executive Summary

Tyrosine Kinase Inhibitors Market was valued at US $48,498.26 million in 2021 and is projected to grow at 10.07% CAGR over the forecast period to reach US $86,262.57 million by 2027. Tyrosine Kinase Inhibitors Market represented US $8,470.55 million opportunity over 2019-2021 and estimated to create US $37,764.31 million opportunity in 2027 over 2021.

Tyrosine Kinase Inhibitors from Consainsights analyses the Tyrosine Kinase Inhibitors Market in the Life Sciences industry over the forecast period to 2027.

Tyrosine Kinase Inhibitors research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Tyrosine Kinase Inhibitors segmentation includes Type, Application and Geography.

Based on the Type, the Tyrosine Kinase Inhibitors analysis covers BCR-ABL Tyrosine Kinase Inhibitor, Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors, Others.

In Type segment, BCR-ABL Tyrosine Kinase Inhibitor segment has highest cagr growth of 8.91%.

Based on the Application, the Tyrosine Kinase Inhibitors analysis covers Chronic Myeloid Leukemia (CML), Lung Cancer, Breast Cancer, Renal Cell Cancer, Others.

In Application segment, Chronic Myeloid Leukemia (CML) segment has highest cagr growth of 8.91%.

Based on the region, the Tyrosine Kinase Inhibitors analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International, Bristol-Myers Squibb Company, Eisai Co, Ltd., F. Hoffmann-La Roche Ltd., Johnson and Johnson, Novartis International AG, Pfizer Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Type

Introduction

In 2021, BCR-ABL Tyrosine Kinase Inhibitor segment has the highest revenue of US $22,735.01 million and is expected to grow at CAGR of 8.91% by 2027 BCR-ABL Tyrosine Kinase Inhibitor segment has highest cagr growth of 8.91%.

BCR-ABL Tyrosine Kinase Inhibitor

BCR-ABL Tyrosine Kinase Inhibitor segment was valued at US $18,764.19 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $40,438.17 million by 2027. BCR-ABL Tyrosine Kinase Inhibitor segment represented US $3,970.82 million opportunity over 2019-2021 and estimated to create US $17,703.15 million opportunity in 2027 over 2021.

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors

Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors segment was valued at US $12,044.08 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $25,955.85 million by 2027. Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors segment represented US $2,548.73 million opportunity over 2019-2021 and estimated to create US $11,363.04 million opportunity in 2027 over 2021.

Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors

Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors segment was valued at US $6,931.57 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $14,938.02 million by 2027. Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors segment represented US $1,466.84 million opportunity over 2019-2021 and estimated to create US $6,539.62 million opportunity in 2027 over 2021.

Others

Others segment was valued at US $2,287.88 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $4,930.54 million by 2027. Others segment represented US $484.15 million opportunity over 2019-2021 and estimated to create US $2,158.51 million opportunity in 2027 over 2021.

Application

Introduction

In 2021, Chronic Myeloid Leukemia (CML) segment has the highest revenue of US $20,638.37 million and is expected to grow at CAGR of 8.91% by 2027 Chronic Myeloid Leukemia (CML) segment has highest cagr growth of 8.91%.

Chronic Myeloid Leukemia (CML)

Chronic Myeloid Leukemia (CML) segment was valued at US $17,033.74 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $36,708.93 million by 2027. Chronic Myeloid Leukemia (CML) segment represented US $3,604.63 million opportunity over 2019-2021 and estimated to create US $16,070.56 million opportunity in 2027 over 2021.

Lung Cancer

Lung Cancer segment was valued at US $11,933.80 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $25,718.18 million by 2027. Lung Cancer segment represented US $2,525.40 million opportunity over 2019-2021 and estimated to create US $11,258.99 million opportunity in 2027 over 2021.

Breast Cancer

Breast Cancer segment was valued at US $6,458.75 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $13,919.08 million by 2027. Breast Cancer segment represented US $1,366.78 million opportunity over 2019-2021 and estimated to create US $6,093.54 million opportunity in 2027 over 2021.

Renal Cell Cancer

Renal Cell Cancer segment was valued at US $3,180.78 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $6,854.80 million by 2027. Renal Cell Cancer segment represented US $673.11 million opportunity over 2019-2021 and estimated to create US $3,000.92 million opportunity in 2027 over 2021.

Others

Others segment was valued at US $1,420.64 million in 2019 and is projected to grow at 8.91% CAGR over the forecast period to reach US $3,061.58 million by 2027. Others segment represented US $300.63 million opportunity over 2019-2021 and estimated to create US $1,340.31 million opportunity in 2027 over 2021.